Rigor Reviewed

Rigor-Reviewed Manuscript

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Name: Αlpha¹ Rigor Record — An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
Item: An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
Rating: 59
Author: Αlpha¹

Li X, Benegiamo G, Vijayakumar A, Sroda N, Kimura M, Huss RS, Weng S, Murakami E, Kirby BJ, von Alvensleben GVG, Kremoser C, Gane EJ, Takebe T, Myers RP, Subramanian GM, Auwerx J

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1.75★ (Critical), 0 critical, 6 high issues for “An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1.75 / 5

Critical — serious problems across many checks

Mixed Methods

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
ReportingKey resources partially met−0.25★
ReportingStatistical analysis partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Problems surfaced7 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed
Study-design details incomplete (controls, blinding, power)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper presents a well-conceived and transparently reported mixed-methods study combining preclinical, genetic, and phase 1 clinical data to evaluate a liver-restricted LXR inverse agonist. Major strengths include a strong scientific premise, clear ethical approvals for the clinical trial, and good data availability. Key weaknesses are incomplete reporting of preclinical randomization/blinding/power, missing cell line authentication and mycoplasma testing (including a misidentified HepG2 line), and imprecise p-value reporting in some figures.

Both reviewers classified the study as mixed; no divergence. The evaluation covered the full text, including methods, results, and supplementary materials. The statistics verification component checked 0 tests (none recomputable from reported statistics), so statistical correctness beyond the reported tests is unverified. The citation check found no retracted or unresolved references. The integrity check flagged a misidentified cell line and a retrospective trial registration, which are incorporated into the relevant dimensions.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions5 pass · 3 warn

The introduction thoroughly reviews prior research on LXR biology, dyslipidemia, and the rationale for LXR inverse agonists, including strengths and limitations of previous approaches. The hypothesis follows logically from the cited evidence, and the paper addresses limitations of prior LXR agonists (e.g., systemic effects on RCT) by developing a liver-restricted compound.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The scientific premise is well established with extensive prior work cited and a clear rationale linking LXR biology to dyslipidemia and the development of TLC-2716.

Evidence

direct quote[Introduction, paragraphs 1-3]

“The liver X receptors (LXRs; LXRα (encoded by NR1H3 ) and LXRβ (encoded by NR1H2 )) are members of the nuclear hormone receptor superfamily and key transcriptional regulators of systemic lipid metabolism”